In a woman older than 65 years, when is hormone replacement therapy indicated, what are the contraindications, and what regimen and monitoring are recommended?

Hormone Replacement Therapy After Age 65

Hormone therapy should generally NOT be initiated after age 65, but women who started therapy before age 60 or within 10 years of menopause may continue if they have persistent bothersome vasomotor symptoms, with the understanding that risks increase with age and duration of use 1, 2.

When HRT is Indicated After Age 65

Continuation (Not Initiation)

• Persistent bothersome vasomotor symptoms (hot flashes, night sweats) that significantly impair quality of life despite previous attempts to discontinue 1, 3
• Women who started therapy appropriately (before age 60 or within 10 years of menopause) and still require symptom control
• Genitourinary syndrome of menopause should be treated with low-dose vaginal estrogen, NOT systemic therapy 2

Critical Distinction

The evidence strongly diverges on late initiation. While one large Medicare study 4 showed mortality and morbidity benefits with continuation beyond 65, a more recent 2026 study 5 demonstrated that initiation after age 65 was associated with dramatically increased risks: cancer (HR 2.22), stroke (HR 2.70), and when started at 50-65 and continued, even higher risks of stroke (HR 16.69), cancer (HR 8.49), and heart disease (HR 9.17). This supports the guideline position that initiation after 65 is inappropriate 1, 2.

Absolute Contraindications

Do not prescribe if any of the following are present 1:

• Unexplained vaginal bleeding
• History of stroke, TIA, MI, PE, or VTE
• Current or history of breast cancer
• Current or history of endometrial cancer
• Active liver disease

Relative Contraindications (Exercise Extreme Caution)

1:

• Diabetes mellitus
• Hypertriglyceridemia
• Active gallbladder disease
• Elevated breast cancer risk (family history, BRCA mutation, dense breasts)
• Elevated cardiovascular disease risk
• Migraine with aura

Recommended Regimens for Women Over 65

If Continuing Therapy:

For women WITHOUT a uterus:

• Estrogen monotherapy (ET) only
• Prefer transdermal or vaginal routes over oral 4
• Use lowest effective dose - low-dose preparations show better risk profiles than medium or high doses 4
• Estradiol (E2) preferred over conjugated equine estrogen 4

For women WITH a uterus:

• Estrogen plus progestogen therapy (EPT) required for endometrial protection 1
• Low-dose transdermal or vaginal estrogen + progestin mitigates breast cancer risk compared to oral preparations 4
• E+ progestin shows risk reductions in endometrial cancer (45%), ovarian cancer (21%), and cardiovascular events 4
• E+ progesterone has less favorable profile than E+ progestin 4

Specific Dosing Strategy:

• Attempt dose reduction or discontinuation periodically - this is considered appropriate even if previously attempted 6
• Start with lowest effective dose
• Vaginal > transdermal > oral in terms of safety profile 4

Monitoring Requirements

Before Initiating/Continuing:

• Cardiovascular risk assessment: Calculate 10-year ASCVD risk, assess for hypertension, diabetes, lipids
• Breast cancer risk assessment: Family history, personal risk factors, mammography status
• Thrombotic risk: History of VTE, thrombophilia, immobility
• Liver function tests if history of liver disease
• Endometrial assessment if unexplained bleeding

During Therapy:

• Annual breast cancer screening (mammography)
• Annual cardiovascular risk reassessment
• Periodic attempts to reduce dose or discontinue - present this option at each visit 6
• Monitor for breakthrough bleeding (requires endometrial evaluation)
• Annual review of indication for continuation

Red Flags Requiring Immediate Discontinuation:

• New cardiovascular event (MI, stroke, TIA)
• VTE or PE
• New breast cancer diagnosis
• Unexplained vaginal bleeding
• New liver dysfunction

Critical Clinical Pitfalls

1. The "timing hypothesis" does NOT apply after 65 - cardiovascular benefits seen with early initiation (within 10 years of menopause) do not translate to late initiation 5, 2, 3

2. Do not confuse systemic therapy with vaginal therapy - genitourinary symptoms should be treated with low-dose vaginal estrogen, which has minimal systemic absorption and different risk profile 2

3. Breast cancer risk increases with EPT duration - this is dose-dependent and can be mitigated with low-dose transdermal preparations 4

4. The 2024 Medicare study showing benefits 4 evaluated continuation, not initiation - the 2026 study 5 specifically showed harm with late initiation

5. "Routine discontinuation at 65" is not recommended 3 - but this applies to women with persistent symptoms who started appropriately, not blanket continuation

Algorithm for Decision-Making

Step 1: Is the patient currently on HRT or requesting initiation?

• If requesting NEW initiation after 65: Generally inappropriate - consider non-hormonal alternatives 1, 5, 2
• If currently on HRT started before 60: Proceed to Step 2

Step 2: Are there absolute contraindications? (See list above)

• If YES: Discontinue immediately
• If NO: Proceed to Step 3

Step 3: What is the indication?

• Persistent bothersome VMS: Proceed to Step 4
• Genitourinary symptoms only: Switch to low-dose vaginal estrogen 2
• Bone protection, cosmetic, libido, memory: Inappropriate - discontinue 6

Step 4: Assess cardiovascular and breast cancer risk

• If HIGH risk: Strongly recommend discontinuation or switch to lowest dose transdermal preparation with close monitoring
• If ACCEPTABLE risk: May continue with dose reduction attempt

Step 5: Optimize regimen

• Switch to lowest effective dose
• Prefer transdermal/vaginal over oral 4
• If uterus present, ensure progestogen protection
• Schedule 6-month follow-up for reassessment and dose reduction attempt